滚动资讯
Thermo FisherTMO Thermo Fisher Scientific Inc falls 2.95 percent post Q4 2025 earnings despite narrow EPS beat and 3.9 percent year-over-year revenue growth. - Investment Community Signals - UBND thành phố Hải PhòngFierceBiotech礼来公司放弃与瑞格生物剩余协议，RIPK1抑制剂再遭打击。Thermo FisherThermo Fisher (TMO) Q4 2024 Earnings Transcript - AOL.comWatersWAT (Waters Corporation) rises 1.06 percent after Q4 2025 results, as 7 percent revenue growth offsets minor EPS miss. - Earnings Risk - Cổng thông tin điện tử Tỉnh Sơn LaFierceBiotech麦克森以12.5亿美元将外科部门少数股权置换给阿波罗基金。FierceBiotechAcuityMD raises $80M to help bolster AI in the medtech industryFierceBiotechAACR: NCI leader Letai battles ‘misinformation’ to assure anxious researchers that ‘funding is strong’FierceBiotechMerck goes with Google for AI push, striking enterprise partnership worth up to $1BBioWorldAppointments and advancements for April 22, 2026BioWorldFinancings for April 22, 2026BioWorldIn the clinic for April 22, 2026BioWorldOther news to note for April 22, 2026
Endpoints News 2026年2月6日

Roivant分拆公司Priovant公布brepocitinib治疗皮肤结节病的二期临床试验数据

Roivant分拆公司Priovant公布brepocitinib治疗皮肤结节病的二期临床试验数据

原文
暂时没有全文，请查看原始来源。